AU2008223915B2 - Process for the synthesis of GLYT-1 inhibitors - Google Patents

Process for the synthesis of GLYT-1 inhibitors Download PDF

Info

Publication number
AU2008223915B2
AU2008223915B2 AU2008223915A AU2008223915A AU2008223915B2 AU 2008223915 B2 AU2008223915 B2 AU 2008223915B2 AU 2008223915 A AU2008223915 A AU 2008223915A AU 2008223915 A AU2008223915 A AU 2008223915A AU 2008223915 B2 AU2008223915 B2 AU 2008223915B2
Authority
AU
Australia
Prior art keywords
formula
compound
alkyl
halogen
room temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008223915A
Other languages
English (en)
Other versions
AU2008223915A1 (en
Inventor
Christophe Pfleger
Pius Waldmeier
Shaoning Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU2008223915A1 publication Critical patent/AU2008223915A1/en
Application granted granted Critical
Publication of AU2008223915B2 publication Critical patent/AU2008223915B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2008223915A 2007-03-05 2008-02-25 Process for the synthesis of GLYT-1 inhibitors Active AU2008223915B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07103485.4 2007-03-05
EP07103485 2007-03-05
PCT/EP2008/052244 WO2008107334A2 (en) 2007-03-05 2008-02-25 Process for the synthesis of glyt-1 inhibitors

Publications (2)

Publication Number Publication Date
AU2008223915A1 AU2008223915A1 (en) 2008-09-12
AU2008223915B2 true AU2008223915B2 (en) 2013-05-02

Family

ID=39469606

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008223915A Active AU2008223915B2 (en) 2007-03-05 2008-02-25 Process for the synthesis of GLYT-1 inhibitors

Country Status (13)

Country Link
US (1) US7812161B2 (cg-RX-API-DMAC7.html)
EP (1) EP2131843B1 (cg-RX-API-DMAC7.html)
JP (1) JP4745446B2 (cg-RX-API-DMAC7.html)
KR (1) KR101143073B1 (cg-RX-API-DMAC7.html)
CN (1) CN101622000B (cg-RX-API-DMAC7.html)
AT (1) ATE532516T1 (cg-RX-API-DMAC7.html)
AU (1) AU2008223915B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0808570B8 (cg-RX-API-DMAC7.html)
CA (1) CA2678630C (cg-RX-API-DMAC7.html)
ES (1) ES2375585T3 (cg-RX-API-DMAC7.html)
IL (1) IL200323A (cg-RX-API-DMAC7.html)
MX (1) MX2009009065A (cg-RX-API-DMAC7.html)
WO (1) WO2008107334A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5656474B2 (ja) 2010-06-28 2015-01-21 関東化学株式会社 脂肪族光学活性フルオロアルコールの製造方法
CN104628679B (zh) * 2013-11-08 2018-02-09 江苏恩华药业股份有限公司 Bitopertin的合成方法及其中间体
CN106397312B (zh) * 2015-07-31 2020-03-24 广东东阳光药业有限公司 一种制备glyt-1抑制剂的方法
CA3166938A1 (en) 2020-01-09 2021-07-15 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
CN116348108A (zh) 2020-10-13 2023-06-27 勃林格殷格翰国际有限公司 再加工方法
CN119768399A (zh) 2022-08-24 2025-04-04 勃林格殷格翰国际有限公司 GlyT-1抑制剂的可规模化制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005014563A1 (en) * 2003-08-11 2005-02-17 F. Hoffmann-La Roche Ag Piperazine with or-substituted phenyl group and their use as glyt1 inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992441A (en) * 1972-12-26 1976-11-16 Pfizer Inc. Sulfamylbenzoic acids
US4480102A (en) * 1982-07-23 1984-10-30 The Dow Chemical Company 2,3-Difluoro-5-(trifluoromethyl)pyridine and methods of making and using the same
IE62792B1 (en) * 1988-11-24 1995-03-08 Akzo Nv Pharmaceutical composition containing 1-(mono- or bis (Trifluoromethyl)-2-pyridinyl) piperazines
DE4235155A1 (de) * 1992-10-19 1994-04-21 Basf Ag Verfahren zur Herstellung von Methylsulfonylbenzoesäuren
TR200003037T2 (tr) * 1998-04-20 2001-01-22 Fujisawa Pharmaceutical Co.,Ltd. CGMP-Fosfodiesteraz önleyicileri olarak antiranilik asit türevleri.
DE10112040A1 (de) 2001-03-14 2002-10-02 Aventis Pharma Gmbh Verbessertes Verfahren zur Herstellung von Sulfonylcarboxamidderivaten
GB0227240D0 (en) * 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
AU2005313581B2 (en) * 2004-12-09 2011-06-09 F. Hoffmann-La Roche Ag Phenyl-piperazin methanone derivatives
MX2007008190A (es) * 2005-01-06 2007-08-07 Hoffmann La Roche Fenil metanonas sustituidas con sulfanilo como inhibidores del transportador de glicina 1 (glyt-1) para el tratamiento de trastornos neurologicos y neuropsiquiatricos.
ATE472327T1 (de) * 2005-01-07 2010-07-15 Hoffmann La Roche Ä4-(heteroaryl)piperazin-1-ylü-(2,5-substituier e phenyl)methanon-derivate als glycin-transporter 1 (glyt-1) hemmer zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
CN101218350B (zh) * 2005-07-08 2011-08-31 弗·哈夫曼-拉罗切有限公司 1,1,1-三氟丙酮的不对称还原反应

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005014563A1 (en) * 2003-08-11 2005-02-17 F. Hoffmann-La Roche Ag Piperazine with or-substituted phenyl group and their use as glyt1 inhibitors

Also Published As

Publication number Publication date
ATE532516T1 (de) 2011-11-15
EP2131843B1 (en) 2011-11-09
BRPI0808570B1 (pt) 2020-09-15
KR20090110368A (ko) 2009-10-21
CA2678630C (en) 2015-04-14
JP2010520251A (ja) 2010-06-10
CN101622000B (zh) 2012-07-04
IL200323A0 (en) 2010-04-29
CN101622000A (zh) 2010-01-06
MX2009009065A (es) 2009-08-31
IL200323A (en) 2013-11-28
US20080221327A1 (en) 2008-09-11
US7812161B2 (en) 2010-10-12
CA2678630A1 (en) 2008-09-12
BRPI0808570A2 (pt) 2014-09-02
EP2131843A2 (en) 2009-12-16
WO2008107334A2 (en) 2008-09-12
BRPI0808570B8 (pt) 2021-05-25
KR101143073B1 (ko) 2012-05-08
JP4745446B2 (ja) 2011-08-10
ES2375585T3 (es) 2012-03-02
WO2008107334A3 (en) 2008-10-23
AU2008223915A1 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
AU2008223915B2 (en) Process for the synthesis of GLYT-1 inhibitors
WO2006136407A1 (en) Process for preparing amorphous rosuvastatin calcium free of impurities
CA2810393C (en) Method of preparing 3-amino-4-(2-oxo-piperidin-1-yl)-butyric acid derivative for synthesizing medicament
ES3014254T3 (en) Process for the preparation of n-[4-(chlorodifluoromethoxy)phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl)pyridine-3-carboxamide
CA2719778C (en) Method for preparing argatroban monohydrate
JP2019147763A (ja) プロリンアミド化合物の製造方法
CA2645154C (en) Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof
CA3175210A1 (en) Synthesis of a monoacylglycerol lipase inhibitor
NO313550B1 (no) Pyrrolidinyl- og pyrrolinyl etylaminforbindelser som kappa- agonister og fremgangsmåte for fremstilling derav, samtfarmasöytisk preparat
CN111233866B (zh) 托法替尼或其盐的制备方法
CN115611858A (zh) 一种全新的尼古丁及其衍生物的制备方法
WO2023226900A1 (zh) 2-(哌嗪-2-基)乙腈类衍生物及其制备方法和应用
JP2010077089A (ja) ハロピラジンカルボキサミド化合物の製造方法
JP7536950B2 (ja) プロリンアミド化合物の製造方法
JP7279134B2 (ja) プロリンアミド化合物の製造方法
KR100743617B1 (ko) 고광학순도를 갖는 키랄 3-히드록시 피롤리딘 및 그유도체를 제조하는 방법
KR100868160B1 (ko) Ｓ-(-)-암로디핀 또는 이의 염의 제조방법 및 이에사용되는 중간체
JP5397706B2 (ja) 高純度１−ベンジル−３−アミノピロリジンの製造方法
ES3010713T3 (en) Isoquinoline sulfonyl chloride acid addition salts and method of manufacture thereof
CN118146258A (zh) 一种精草铵膦的制备方法
CA3161387A1 (en) Process for the preparation of purine derivatives exhibiting cdk inhibitory activity
EP1634879A1 (en) Method of selectively introducing amino substituent

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)